Slowing revenue growth hurts online drug platform YSB
The B2B drug distributor posted higher annual revenues and swung to an adjusted profit, but disappointed investors still sent the firm’s stock down 9% on the day after the earnings…
9885.HK
Recent Articles
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Fourth Paradigm tries to shift investor perception with new platform launch
6682.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
GigaCloud’s business shines, but investors still rain on its parade
GCT.US
Discover hidden China stock gems in our weekly newsletter